A new synthetic route to obtaining megazol, an drug active in negligence’s disease


A new synthetic route to obtaining megazol, an drug active in negligence’s disease

New drugs are urgently required for treatment of human African trypanosomiasis and Chagas´ disease. One compound with promise is megazol, a nitro heterocyclic compound that forms a nitro radical anion upon reduction. Megazol (2-amino-5-(1-methyl-5-nitro-2-imidazolyl)- 1,3,4-thiadiazol) and related nitroimidazole compounds are being tested as antichagasic drugs. Little is known on the mode of action of megazol. However, there is evidence that 1-electron reduction of megazol to the corresponding nitro radical anion is a key step in the reaction mechanism. It was observed that the obtaining of megazol can be made by different paths synthetic modifying procedures and reagents involved in the chemistry of heterocyclic particularly imidazoles. We evaluated experimental conditions, partial and overall income, as well as the characteristics of reagents involved in the processes indicated in one of the routes. Megazol was prepd. from 1-methylimidazole by cyanation, cyclization with thiosemicarbazide, nitration with concomitant acetylating of the amino group, and deacetylation

Asian Journal of Biomedical and Pharmaceutical Science accept Editorial, letter, case reports, short communications, original and review articles from leading scientists and scholars around the world in all areas of food, nutrition, biochemistry, physiology, pathology and medicine.

Authors can directly submit the article as an attachment to this online: https://www.scholarscentral.org/submissions/asian-biomedical-pharmaceutical-sciences.html

The articles once published can be accessed freely.

Media Contact:
Annie Grace Sarah
Journal Manager
Asian Journal of Biomedical and Pharmaceutical Sciences
Email: jbiopharm@epharmajournal.com